Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · May 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how certain genetic variations, known as genomic polymorphisms, might be related to a serious condition called cancer cachexia in patients with pancreatic adenocarcinoma, a type of cancer that starts in the pancreas. Cancer cachexia is a complex syndrome that leads to significant weight loss, muscle loss, and weakness that cannot be fixed through regular nutrition. It affects more than 75% of patients with advanced pancreatic cancer, making it a major concern for improving patient outcomes.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of pancreatic adenocarcinoma, either locally advanced or metastatic (meaning it has spread). Participants will be asked to provide a blood or cheek swab sample for analysis. By collecting and studying these samples, researchers hope to discover genetic factors that contribute to cancer cachexia, which could eventually lead to better treatments and ways to support patients dealing with this challenging condition. If you or a loved one are interested in learning more or possibly participating, this trial is currently recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Subject must meet all of the following applicable inclusion criteria to participate in this study:
• • Written informed consent and HIPAA authorization for release of personal health information by the subject in accordance with the practices of the Levine Cancer Institute and Atrium Health. NOTE: HIPAA authorization will be included in the informed consent.
• • Male or female patients age ≥ 18 years at the time of consent
• • Histological or cytological confirmation of pancreatic adenocarcinoma, with a diagnosis of locally advanced unresectable PDAC (LAPC) or metastatic pancreatic adenocarcinoma. LAPC is defined as per NCCN 16. Note: Subject can be enrolled at any time during their cancer course following histologic diagnosis.
• • Able to provide a blood or buccal sample.
• Exclusion Criteria:
• • None